Sighting acute myocardial infarction through platelet gene expression. by Gobbi, Giuliana et al.
Thomas Jefferson University 
Jefferson Digital Commons 
Department of Cancer Biology Faculty Papers Department of Cancer Biology 
12-2019 
Sighting acute myocardial infarction through platelet gene 
expression. 
Giuliana Gobbi 
Cecilia Carubbi 
Guidantonio Malagoli Tagliazucchi 
Elena Masselli 
Prisco Mirandola 
See next page for additional authors 
Follow this and additional works at: https://jdc.jefferson.edu/cbfp 
 Part of the Other Medical Sciences Commons 
Let us know how access to this document benefits you 
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital 
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is 
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections 
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested 
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been 
accepted for inclusion in Department of Cancer Biology Faculty Papers by an authorized administrator of the 
Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu. 
Authors 
Giuliana Gobbi, Cecilia Carubbi, Guidantonio Malagoli Tagliazucchi, Elena Masselli, Prisco Mirandola, 
Filippo Pigazzani, Antonio Crocamo, Maria Francesca Notarangelo, Sergio Suma, Elvezia Paraboschi, 
Giuseppe Maglietta, Srikanth Nagalla, Giulia Pozzi, Daniela Galli, Mauro Vaccarezza, Paolo Fortina, Sankar 
Addya, Adam Ertel, Paul Bray, Stefano Duga, Carlo Berzuini, Marco Vitale, and Diego Ardissino 
1Scientific RepoRtS |         (2019) 9:19574  | https://doi.org/10.1038/s41598-019-56047-0
www.nature.com/scientificreports
Sighting acute myocardial 
infarction through platelet gene 
expression
Giuliana Gobbi1, cecilia carubbi1, Guidantonio Malagoli tagliazucchi2,3, elena Masselli1, 
prisco Mirandola1, filippo pigazzani  2, Antonio crocamo2, Maria francesca notarangelo2, 
Sergio Suma2, elvezia paraboschi2,4, Giuseppe Maglietta3,5, Srikanth nagalla6, Giulia pozzi1, 
Daniela Galli1, Mauro Vaccarezza  7, paolo fortina  8,9, Sankar Addya8, Adam ertel8, 
paul Bray10, Stefano Duga  4, carlo Berzuini  11, Marco Vitale1* & Diego Ardissino2
Acute myocardial infarction is primarily due to coronary atherosclerotic plaque rupture and subsequent 
thrombus formation. platelets play a key role in the genesis and progression of both atherosclerosis and 
thrombosis. Since platelets are anuclear cells that inherit their mRnA from megakaryocyte precursors 
and maintain it unchanged during their life span, gene expression profiling at the time of an acute 
myocardial infarction provides information concerning the platelet gene expression preceding the 
coronary event. in St-segment elevation myocardial infarction (SteMi), a gene-by-gene analysis of the 
platelet gene expression identified five differentially expressed genes: FKBP5, S100P, SAMSN1, CLEC4E 
and S100A12. The logistic regression model used to combine the gene expression in a STEMI vs healthy 
donors score showed an AUC of 0.95. The same five differentially expressed genes were externally 
validated using platelet gene expression data from patients with coronary atherosclerosis but without 
thrombosis. Platelet gene expression profile highlights five genes able to identify STEMI patients and 
to discriminate them in the background of atherosclerosis. consequently, early signals of an imminent 
acute myocardial infarction are likely to be found by platelet gene expression profiling before the 
infarction occurs.
Acute myocardial infarction is a sudden event that is fatal in approximately one-third of patients, with about half 
of the deaths occurring within one hour. It is frequently attributed to coronary atherosclerotic plaque rupture and 
the consequent exposure of thrombogenic substances that promote platelet activation/aggregation, the activation 
of coagulation and, ultimately, the formation of an intraluminal thrombus that limits coronary blood flow1,2. 
However, although plaque rupture or fissuring frequently occurs in atherosclerosis, only a small proportion of 
ruptured plaques results in thrombosis. Autopsy data show that a sizable proportion of the subjects who die sud-
denly of non-cardiac causes have fissured plaques without thrombosis in their coronary arteries3. The rupture of 
coronary atherosclerotic plaque is therefore much more frequent than thrombus formation. It has been suggested 
that individual reactivity to plaque rupture may play a causative role in provoking the clinical event of acute 
myocardial infarction4–8.
Platelets are key mediators of hemostasis that contribute to the genesis and progression of atherosclerosis, 
and the precipitation of an atherothrombotic event after plaque rupture1,2,9. Platelets are anuclear cells formed 
from the cytoplasm of megakaryocytes (MKs) and circulate in the blood stream for about 7–10 days10. Despite 
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the absence of a nucleus, platelets contain RNAs, including messenger RNA (mRNA), long non-coding RNA 
and micro-RNA, and protein synthesis machinery accounting for more than 9,000 transcripts in healthy human 
donors11–13. Platelet mRNA is primarily derived from MKs: indeed, genome-wide expression studies of platelets 
and MK-derived cultures from CD34 + hematopoietic progenitor cells, have shown that about half of the approx-
imately 10,000 transcripts present in MKs can also be found in platelets14,15.
Platelet transcriptome alterations have been associated with specific human phenotypes such as coronary 
artery disease16–18, atrial fibrillation19, essential thrombocythemia20, systemic lupus erythematosus21 and sickle 
cell anemia22. The transcriptional profiling of platelets provides information concerning the gene expression that 
precedes an acute coronary event without the confounding possibility of de novo gene transcription. This study 
was therefore designed to test the hypothesis that platelet transcriptome contains the gene signature of an immi-
nent myocardial infarction.
Results
The gene that showed the strongest evidence of differential expression between the ST-segment elevation myo-
cardial infarction (STEMI) and healthy donors (HD) groups (Table 1) was FKBP5 (odds ratio: 204.06; 95% 
confidence interval 12.11–15705.95; p = 0.0026), followed by S100P (odds ratio: 3.35; 95% confidence interval 
1.48–9.25; p = 0.0082), SAMSN1 (odds ratio: 2.76; 95% confidence interval 1.42–6.53; p = 0.0075), S100A12 
(odds ratio: 2.35; 95% confidence interval 1.51–4.52; p = 0.0017) and CLEC4E (odds ratio:1.97; 95% confidence 
interval 1.26–3.47; p = 0.0079) (Fig. 1, panel a and Supplemental Table 1). A logistic regression model based on 
the five genes was capable of discriminating the STEMI patients from HDs with an area under the curve (AUC) 
of 0.95 (95% confidence interval 0.62–1.00) (Fig. 2, panel a). These results were internally validated by means of a 
bootstrap analysis that took gene selection into account. Additionally, we found that the expression levels of these 
five genes were independent from the time of blood withdrawn (Supplemental Fig. 1). Moreover, we tested the 
correlation levels between the expression of each of the five identified genes and CK-MB and Troponin I circulat-
ing levels. No statistically significant correlation was found except for S100P vs CK-MB (p = 0.56, p = 0.0120) and 
S100P vs Troponin I (p = 0.5700, p = 0.0110) (Supplemental Fig. 2), in agreement with a previous study on a rat 
model with ischemia-reperfusion injury23.
The ability of the five identified genes to discriminate subjects with enhanced reactivity to plaque rupture was 
externally confirmed using data from a further 20 patients with stable coronary artery disease (SCAD), the pheno-
typically closest condition to STEMI (Fig. 1, panel b). The logistic model based on these five genes was capable of dis-
criminating the STEMI and SCAD groups with an AUC of 0.93 (95% confidence interval 0.60–1.00) (Fig. 2, panel b).
Discussion
Here, we first report five differentially expressed genes (DEGs) on platelet transcriptome able to identify STEMI 
patients from HD. It is worth noting that all 5 DEGs were already known to be associated with cardiovascular 
conditions: S100A12 with coronary artery disease (CAD) and atherosclerotic plaques24; FKBP5 with STEMI25; 
CLEC4E and SAMSN1 with atherosclerotic lesions26,27; and S100P with acute coronary syndrome (ACS)23 
(Table 2). Overall, analysis of platelet gene expression reveals quantitative differences that immediately precede 
the occurrence of an acute myocardial infarction.Indeed, our data and the existing literature16,23,24 strongly sug-
gested that S100 protein family28 is a relevant player in cardiovascular risk29 and thrombus formation both in 
mouse30 and ACS patients31. However, S100 protein family demonstrated a poor perfomance as a biomarker 
in emergency settings32,33. On the contrary, this panel of 5 DEGs allowed a successful sorting of cardiovascular 
events.
In fact, the simultaneous up-regulation of these five genes, which are known simultaneous up-regulation of 
these five genes, which are known to be associated with cardiovascular conditions, identified STEMI patients 
and, in a background of coronary atherosclerosis, discriminated those with or without thrombosis. A limitation 
of our study is the relatively small sample size, and we are aware that our five genes set has to be validated in larger 
population cohorts of STEMI subjects and in cohorts of subjects with different degrees of cardiovascular risk. 
We are also aware that our healthy donor controls could not be the best comparator due to confounding by 
medications. Non-ACS chronic CAD patients matched for age and medications might be a better comparator 
to further confirm our results. However, it is our opinion that the stringent inclusion criteria (i.e. blood samples 
processing within 6 hours; absence of pharmacological treatments before symptoms onset and sample collection) 
as well as exclusion criteria (as reported in the Methods Section, we excluded all the STEMI patients under 
anti-thrombotic/anti-coagulant treatment and/or anti-platelet drugs [except aspirin, which is mandatory based 
on current guidelines] before the time of hospital admission) adopted generated the solid evidence reported. Even 
if data from the literature reported that aspirin could affect mRNA and protein expression of megakaryocytes and 
platelets34–36, our results unequivocally distinguished STEMI patients from healthy donors (all without aspirin 
treatment) and from SCAD patients (all on aspirin treatment). Therefore, we believe that aspirin did not interfere 
with the concurrent differential expression of the five identified genes.
This is the first study demonstrating that platelets gene expression contains useful information to predict an 
unexpected clinical event such as MI. So far, no other biomarkers proved to be able to predict plaque rupture, 
the underlying mechanism of acute MI. The logical next step will be a prospective clinical validation in a larger 
population at high risk for MI and moreover, future studies are also needed to clarify whether the five identified 
genes have causative role or are simply markers of the acute event to happen. Notwithstanding these caveats, the 
translational relevance of our findings pre-dating myocardial infarction is evident per se and might well repre-
sent a valuable predictor for this still unpredictable disease and shed a light into the biological underpinning of 
acute myocardial infarction that precede current diagnostic tools and potentially lead to changes in the way we 
approach patients with suspected heart attack in the future.
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Methods
patient selection. Three groups of subjects were studied: (1) twenty patients with ST elevation myocar-
dial infarction (STEMI); (2) twenty healthy donor (HD); (3) twenty patient with stable coronary artery disease 
(SCAD).
All subjects were enrolled at the Cardiology Division of the Azienda Ospedaliero-Universitaria of Parma. 
This study was performed according to the Declaration of Helsinki, the protocol was approved by the Ethical 
Committee of Parma University Hospital and subjects were enrolled after written informed consent.
Between June 2014 and October 2015, we prospectively enrolled 20 patients with ST elevation myocardial 
infarction (STEMI) defined as typical chest pain with the following electrocardiographic criteria: a new ST seg-
ment elevation at the J point in two contiguous leads, with cut-off points of >0.1 mV in all leads other than leads 
V2-V3, for which the cut-off points were ≥0.2 mV in men aged ≥40 years, ≥0.25 mV in men aged <40 years, 
STEMI HD SCAD
Number of patients, n 20 20 20
Age, median (range) 65.5 (51–82) 62.5 (49–81) 63.5 (51–80)
Gender
Male, n (%) 15 (75) 15 (75) 15 (75)
Female, n (%) 5 (25) 5 (25) 5 (25)
Family history
n (%) 7 (35) 0 (0) 3 (15)
Hypertension
n (%) 11 (55) 0 (0) 17 (85)
Smoking
n (%) 10 (50) 0 (0) 3 (15)
Dyslipidemia
n (%) 9 (45) 0 (0) 11 (55)
Diabetes Mellitus
n (%) 5 (25) 0 (0) 7 (35)
Obesity
n (%) 2 (10) 0 (0) 3 (15)
ST elevation
Inferior- lateral, n (%) 3 (15) no no
Anterior, n (%) 9 (45) no no
Inferior, n (%) 7 (35) no no
Lateral, n (%) 1 (5) no no
Angiography
CX occlusion, n (%) 4 (20) n/a 1 (5)
LAD occlusion, n (%) 9 (45) n/a 10
RCA occlusion, n (%) 7 (35) n/a 1
CX, LAD 0 n/a 2
CX, RCA 0 n/a 1
LAD, RCA 0 n/a 1
CX, LAD, RCA 0 n/a 4
Thrombosis
n (%) 20 (100) n/a no
CK-MB, mean ± SD 172.39 ± 95.30 normal normal
Tn I, mean ± SD 48.44 ± 28.32 normal normal
Aspirin
n (%) 6 (30) 0 (0) 20 (100)
P2Y12 Inhibitors
n (%) 0 (0) 0 (0) 0 (0)
Anticoagulants
n (%) 0 (0) 0 (0) 0 (0)
Table 1. Clinical, electrocardiographic, and angiographic variables of the patients. Family history of ischemic 
heart disease in a first-degree relative before 55 years in men and before 65 years in women; ST elevation: 
location of ST elevation; CX: circumflex coronary artery; LAD: left anterior descending coronary artery; RCA: 
right coronary artery; Thrombosis: presence of coronary thrombosis at angiography; CK-MB: CK-MB peak in 
ng/mL; Tn-I: Troponin I peak in ng/ml. Aspirin: patients on treatment with aspirin; P2Y12 Inhibitors: patients 
on treatment with P2Y12 inhibitors; Anticoagulants: patients on treatment with anticoagulants n: number of 
patients. N/A: not applicable.
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or ≥0.15 mV in women37. Before coronary angiography, all of the patients underwent arterial blood sampling 
(50 mL) within one our from the hospital admission. For all STEMI patients, the time to chest pain/symptoms 
onset ranged from 1 to 6 hours before sample collection. The samples were collected before the administration of 
any anticoagulant or antiplatelet drugs (except acetylsalicylic acid given before hospital arrival). All blood sam-
ples have been processed within one hour of collection.
Each STEMI patient (Supplemental Table 2) was sex- and age-matched (±3 years) with a healthy donor (HD) 
(Supplemental Table 3) and a patient with stable coronary artery disease (SCAD) (Supplemental Table 4).
The HDs were defined as subjects without a previous history of cardiovascular diseases and without any risk 
factors for ischemic heart diseases. All the HD samples collection were planned within one-hour from medical 
examination. The HDs underwent venous blood sampling (50 mL), and all of the samples were processed within 
one hour of collection. The HDs were not taking any drugs (Supplemental Table 3).
SCAD was defined as a documented coronary artery stenosis of >70% in at least one epicardial main artery 
and documented inducible ischemia and/or symptoms without any characteristic of unstable disease38 (i.e. tro-
ponin elevation, rest angina, new-onset angina, recent onset of moderate-to-severe angina, or crescendo angina). 
All the SCAD samples collection were planned within one-hour from medical examination. The SCAD patients 
underwent venous blood sampling (50 mL), and all of the samples were processed within one hour of collection. 
At the time of sampling, all of the patients with SCAD were on aspirin and none of them were taking a P2Y12 
inhibitor or anticoagulant (Supplemental Table 4).
Patients characteristics and their cardiovascular risk factors are reported in Table 1.
Sample source and platelet purification. Citrate anti-coagulated blood samples (50 mL) were taken 
from each subject and collected in vacutainers (BD Vacutainer, Becton Dickinson, San Diego, CA) at a final 
sodium citrate concentration of 3.8%.
Leukocyte depletion was used to obtain highly purified platelets, as previously described39,40. The 
leucocytes-depleted platelets were treated with an appropriate amount of TRIzolTM (Invitrogen) for cell lysis and 
RNA cryopreservation.
Quantitative real-time polymerase chain reaction (pcR). RNA was extracted from leucocytes-depleted 
platelets using TRIzolTM (Invitrogen), as previously described39. The RNA was reverse-transcribed and 
semi-quantitative real-time RT-PCRs were performed to detect the expression levels of CLEC4E, FKBP5, SAMSN1, 
S100A12 and S100P using the SYBR Premix Ex Taq II (Takara, Shiga, Japan) and a LightCycler 480 (Roche, Basel, 
Figure 1. Gene expression values of the five identified genes. Panel a: Individual gene expression values in 
STEMI patients (red), and healthy subjects (green) with median values and interquartile ranges of the five 
identified genes. Panel b: Individual gene expression values in STEMI patients (red), and SCAD patients 
(orange) with median values and interquartile ranges of the five identified genes.
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Switzerland). ACTB (Actin Beta) and ITGA2B (Integrin, Alpha 2b, Platelet Glycoprotein IIb of IIb/IIIa Complex, 
Antigen CD41) were used as housekeeping genes; the reactions were performed in triplicate, and the expression 
data were analysed and rescaled using GeNorm software41 (Supplemental Fig. 3).
Microarray hybridisation. RNA was extracted using TRIzolTM (Invitrogen) in accordance with the man-
ufacturer’s protocol, quantified on a Nanodrop ND-100 spectrophotometer, and quality assessed by means of 
analysis on an Agilent 2200 TapeStation (Agilent Tehnologies, Palo Alto, CA). Fragmented biotin-labelled cDNA 
was synthesised using the GeneChip WT Pico kit (Affymetrix, Santa Clara, CA). Affymetrix gene chips (Human 
Transcriptome Array 2.0, Affymetrix, Santa Clara, CA) were hybridised with fragmented and biotin-labelled 
cDNA. The chips were scanned by an Affymetrix Gene Chip Scanner 3000 using Command Console Software. 
The experiment was quality controlled using Expression Console Software v 1.4.1.
Microarray data processing. The expression data obtained from the Affymetrix probe-sets (70,523) were 
processed using Expression Console software (Affymetrix, www.affymetrix.com) with the default parameters. 
The data are available at GEO, Accession No. GSE109048
Statistical analysis. The expression levels of the 10% most variably expressed genes42 were collected into a 
38 × 6,754 matrix whose rows corresponded to the individual samples and columns corresponded to the selected 
genes, plus a column for individual STEMI-HD status. Simple logistic regression models43 were used to test 
each of the 6,753 expression variables for any association with the STEMI vs HD indicator. There were 51 gene 
Figure 2. Receiver operating characteristic (ROC) curve for discriminating STEMI from HD and from SCAD. 
(a) The area under the ROC curve (AUC) of the capacity of the five identified genes to discriminate STEMI 
patients and HD (red line). AUC of 0.95 (95% confidence interval 0.62–1.00). (b) The area under the ROC curve 
(AUC) of the capacity of the five identified genes to discriminate STEMI and SCAD patients (red dotted line). 
AUC of 0.93 (95% confidence interval 0.60–1.00).
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expression variables with a p-value of <0.05 (Supplemental Table 4) and five with a p-value of <0.01. The later 
were considered for the subsequent stage of analysis, in which they acted as explanatory variables in a multiple 
logistic regression model for the log-odds ratio of the risk of STEMI vs HD. The model was internally validated 
by means of bootstrap resampling44,45. We then ran 30,000 iterations of a bootstrap procedure, each iteration 
involving resampling with the replacement of the rows of the original data matrix in such a way as to preserve the 
original matched structure, and analysed the simulated dataset using the same procedure as that applied to the 
original dataset. The 30,000 bootstrapped Area Under curve (AUC) statistics were used to calculate an empirical 
mean value and 95% confidence interval for the “true” AUC value. Finally, our logistic predictor of the risk of 
STEMI vs HD was assessed in terms of its ability to discriminate STEMI from SCAD as an external validation of 
the model. This involved the use of data from further patients with SCAD – the phenotypically closest condition 
to STEMI with documented coronary atherosclerosis but without thrombosis (Fig. 1, panel b). In this analysis, 
the logistic predictor was used with the gene-specific coefficients fixed at the values estimated on the basis of the 
STEMI vs HD analysis. The analyses were made using custom R-scripts and R-3.3.246.
Reticulated platelet analysis. Aliquots of whole blood were stained with thiazole orange (TO) and 
analysed by means of flow cytometry in order to identify reticulated platelets47–49, as previously described40 
(Supplemental Fig. 4).
For detailed methods see “Supplemental Material”.
ethical approval and informed consent statement. The authors stated that this study was performed 
according to the Declaration of Helsinki, all experimental protocols were approved by the Ethical Committee of 
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(FK506 binding protein 5)
A member of the immunophilin protein family, it plays a role 
in immunoregulation and basic cell processes involving protein 
folding and trafficking.
More frequent in STEMI than NSTEMI platelets in an RNA-seq 
analysis of platelet transcriptome in patients with acute myocardial 
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CLEC4E
(C-type lectin domain family 4 
member E)
Involved in cell adhesion, cell-cell signalling, glycoprotein 
turnover, inflammation and immune response.
CLEC4E is expressed in human and mouse atherosclerotic lesions 
and is activated by necrotic lesion extracts. It plays a critical role 
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aggravates atherosclerotic lesion inflammation.
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(SAM domain, SH3 domain and 
nuclear localisation signals 1)
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of proteins, localised in the cytoplasm and/or nucleus of a wide 
range of cells and is involved in regulating a number of cell 
processes such as cell cycle progression and differentiation. In 
addition to binding Ca2+, this protein also binds Zn2+ and Mg2+.
Serum levels of S100B, S100A6 and S100P are higher in patients 
with acute coronary syndrome than in patients with stable angina 
or control subjects. The expression of these proteins is related to 
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rat models of myocardial infarction.
23
Table 2. Functional annotation of the five identified genes. Functional annotation of the five genes identified in 
the STEMI vs HD analysis with a p-value of < 0.01.
7Scientific RepoRtS |         (2019) 9:19574  | https://doi.org/10.1038/s41598-019-56047-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
 10. Machlus, K. R. & Italiano, J. E. The incredible journey: From megakaryocyte development to platelet formation. J. Cell. Biol. 201, 
785–796 (2013).
 11. Denis, M. M. et al. Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets. Cell. 122, 379–391 
(2005).
 12. Rowley, J. W. et al. Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes. Blood. 118, 101–111 (2011).
 13. Bray, P. F. et al. The complex transcriptional landscape of the anucleate human platelet. BMC Genomics 14, 1 (2013).
 14. Gnatenko, D. V. et al. Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood. 101, 
2285–2293 (2003).
 15. Burns, P. et al. Bloodomics Consortium. Watkins on behalf of the Bloodomics Consortium. Identification of variation in the platelet 
transcriptome associated with glycoprotein 6 haplotype. Platelets. 19, 258–267 (2008).
 16. Healy, A. M. et al. Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of 
cardiovascular events. Circulation. 113, 2278–2284 (2006).
 17. Colombo, G. et al. Gene expression profiling reveals multiple differences in platelets from patients with stable angina or non-ST 
elevation acute coronary syndrome. Thromb. Res. 128, 161–168 (2011).
 18. McManus, D. D. et al. Relationship among circulating inflammatory proteins, platelet gene expression, and cardiovascular risk. 
Arterioscler Thromb Vasc Biol. 33(11), 2666–2673 (2013).
 19. Wysokinski, W. E. et al. Impact of atrial fibrillation on platelet gene expression. Eur. J. Haematol. 98, 615–621 (2017).
 20. Gnatenko, D. V. et al. Platelets express steroidogenic 17 beta-hydroxysteroid dehydrogenases. Distinct profiles predict the essential 
thrombocythemic phenotype. Thromb. Haemost. 94, 412–421 (2005).
 21. Lood, C. et al. Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: up-regulation 
of the type I interferon system is strongly associated with vascular disease. Blood. 116, 1951–1957 (2010).
 22. Raghavachari, N. et al. Amplified expression profiling of platelet transcriptome reveals changes in arginine metabolic pathways in 
patients with sickle cell disease. Circulation. 115, 1551–1562 (2007).
 23. Cai, X. Y. et al. Association of increased S100B, S100A6 and S100P in serum levels with acute coronary syndrome and also with the 
severity of myocardial infarction in cardiac tissue of rat models with ischemia-reperfusion injury. Atherosclerosis. 217, 536–542 
(2011).
 24. Goyette, J. et al. Pleiotropic roles of S100A12 in coronary atherosclerotic plaque formation and rupture. J. Immunol. 183, 593–603 
(2009).
 25. Eicher, J. D. et al. Characterization of the platelet transcriptome by RNA sequencing in patients with acute myocardial infarction. 
Platelets. 27, 230–239 (2016).
 26. Clément, M. et al. Necrotic cell sensor CLEC4E promotes a proatherogenic macrophage phenotype through activation of the 
unfolded protein response. Circulation. 134, 1039–1051 (2016).
 27. Fu, S. et al. Peripheral arterial occlusive disease: global gene expression analyses suggest a major role for immune and inflammatory 
responses. BMC Genomics. 9, 369 (2008).
 28. Marenholz, I., Heizmann, C. W. & Fritz, G. S100 proteins in mouse and man: from evolution to function and pathology (including 
an update of the nomenclature). Biochem Biophys Res Commun. 322(4), 1111–1122 (2004).
 29. Croce, K. et al. Myeloid-related protein-8/14 is critical for the biological response to vascular injury. Circulation. 120(5), 427–436 
(2009).
 30. Wang, Y. et al. Platelet-derived S100 family member myeloid-related protein-14 regulates thrombosis. J Clin Invest. 124(5), 
2160–2171 (2014).
 31. Sakuma, M. et al. Myeloid-related protein-8/14 in acute coronary syndrome. Int J Cardiol. 249, 25–31 (2017).
 32. Vora, A. N. et al. Diagnostic evaluation of the MRP-8/14 for the emergency assessment of chest pain. J Thromb Thrombolysis. 34(2), 
229–34 (2012).
 33. Carubbi, C. et al. Combination of Platelet expression of PKCepsilon and cardiac troponin-I for early diagnosis of chest pain patients 
in the emergency department. Sci Rep. 9(1), 2125 (2019).
 34. Massimi, I. et al. Aspirin-Dependent Effects on Purinergic P2Y1 Receptor Expression. Thromb Haemost. 119, 726–734 (2019).
 35. Massimi, I. et al. Aspirin influences megakaryocytic gene expression leading to up-regulation of multidrug resistance protein-4 in 
human platelets. Br J Clin Pharmacol. 78, 1343–1353 (2014).
 36. Lowenstern, A. et al. Platelet-related biomarkers and their response to inhibition with aspirin and p2y(12)-receptor antagonists in 
patients with acute coronary syndrome. J Thromb Thrombolysis. 44, 145–153 (2017).
 37. Thygesen, K. et al. The Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of 
Myocardial Infarction. Third universal definition of myocardial infarction. Circulation. 126, 2020–2035 (2012).
 38. Montalescot, G., Sechtem, U. & Achenbach, S. ESC guidelines on the management of stable coronary artery disease. European. 
Heart. Journal. 34, 2949–3003 (2013).
 39. Carubbi, C. et al. Protein kinase C ε expression in platelets from patients with acute myocardial infarction. PLoS One. 7, e46409 
(2012).
 40. Carubbi, C. et al. Cytofluorimetric platelet analysis. Semin. Thromb. Hemost. 40, 88–98 (2014).
 41. Vandesompele, J. et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal 
control genes. Genome. Biol. 3, RESEARCH0034 (2002).
 42. Bourgon, R., Gentleman, R. & Huber, W. Independent filtering increases detection power for high-throughput experiments. Proc. 
Natl. Acad. Sci. USA 107, 9546–9551 (2010).
 43. Liao, J. G. & Chin, K. V. Logistic regression for disease classification using microarray data: model selection in a large p and small n 
case. Bioinformatics. 23, 1945–1951 (2007).
 44. Efron, B. Better bootstrap confidence intervals. J. Am. Stat. Assoc. 82, 171–200 (1987).
 45. Berrar, D. & Flach, P. Caveats and pitfalls of ROC analysis in clinical microarray research (and how to avoid them). Brief Bioinform. 
13, 83–97 (2012).
 46. R Core Team R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria., 
https://www.R-project.org/ (2017).
 47. Gonzalez-Porras, J. R. et al. The role of immature platelet fraction in acute coronary syndrome. Thromb. Haemost. 103, 247–249 
(2010).
 48. Cesari, F. et al. Reticulated platelets predict cardiovascular death in acute coronary syndrome patients. Insights from the AMI-
Florence 2 Study. Thromb. Haemost. 109, 846–853 (2013).
 49. Hoffmann, J. J. Reticulated platelets: analytical aspects and clinical utility. Clin. Chem. Lab. Med. 52, 1107–1117 (2014).
Acknowledgements
This work was supported by Programma di ricerca Regione-Università, Regione Emilia-Romagna, bando 
Ricerca Innovativa 2010–2012 “Cardiovascular genetics: from bench to bedside - Genomics & transcriptomics of 
ischemic heart disease” - CUP E35E09000880002.
8Scientific RepoRtS |         (2019) 9:19574  | https://doi.org/10.1038/s41598-019-56047-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
Author contributions
G.G., designed the research, interpreted the data and wrote the manuscript; C.C., E.M., G.P. and D.G. processed 
the samples and performed the experiments; M.Vaccarezza., revised the manuscript; G.T.M. and G.M. performed 
statistical analysis, interpreted the data and prepared the figures; P.M. interpreted the data; F.P., A.C., M.F.N. 
and S.S. provided patients’ sample and data; E.P., performed the experiments and prepared figure; S.A. and A.E. 
performed the experiments; S.N. performed the experiments and revised the manuscript; P.F., P.B. and S.D. 
revised the manuscript; C.B. advised research and statistics; M.V. advised the research and revised the manuscript; 
D.A. provided patients’ sample, designed the study, interpreted the data, and wrote the manuscript.
competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-019-56047-0.
Correspondence and requests for materials should be addressed to M.V.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
